TRCT
RGNT

Tower Research Capital (TRC)’s Regentis Biomaterials RGNT Stock Holding History

Tower Research Capital (TRC)’s Portfolio RGNT Stock Details RGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39 Buy
+11
New +$31 ﹤0.01% 5156

Other funds holding RGNT

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s RGNT Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Regentis Biomaterials (RGNT) in Q2 2026: 11 shares worth $39. The stake represents ﹤0.01% of the portfolio and ranks #5156 among its holdings.

6 funds tracked by Wall St. Rank hold RGNT as of Q2 2026.

  • Tower Research Capital (TRC) held 11 shares of Regentis Biomaterials worth $39 as of Q2 2026.
  • Regentis Biomaterials was a new Tower Research Capital (TRC) position in Q2 2026.
  • Regentis Biomaterials made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #5156 holding.
  • 6 funds tracked by Wall St. Rank held Regentis Biomaterials as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.